The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
April 27, 2023
April 27, 2024
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Lilly.
- Physicians — maximum of 1.5 AMA PRA Category 1 Credits™
- Nurses - 1.5 contact hours
All other healthcare professionals completing this course will be issued a statement of participation.
This educational activity is directed toward geriatric psychiatrists, geriatricians, psychiatrists, psychologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with, or at risk of developing, Alzheimer disease.
A variety of proteins related to various aspects of Alzheimer disease (AD) pathophysiology have been suggested as biomarkers for the condition. Cerebrospinal fluid biomarkers reflect the 3 well-established hallmarks of AD. This symposium features experts reviewing state-of-the-science on the role of new and emerging fluid biomarkers in AD.
This educational activity is an archive of the live virtual symposium held on March 4, 2023.
Upon successful completion of this activity, you should be better prepared to:
- Identify the role of fluid biomarkers in the diagnosis of Alzheimer disease
- Assess clinical trial data for the fluid biomarkers currently available for the diagnosis of Alzheimer disease
- Integrate fluid biomarkers into management plans for patients with suspected Alzheimer disease
Gary Small, MD
Chair of Psychiatry
Hackensack University Medical Center
Chair and Professor of Psychiatry
Hackensack Meridian School of Medicine
Behavioral Health Physician-in-Chief
Hovnanian Family Foundation Endowed Chair in Behavioral Health
Hackensack Meridian Health
Elaine Peskind, MD
Co-director, Mental Illness Research, Education, and Clinical Center
VA Puget Sound Health Care System
Friends of Alzheimer's Research Professor of Psychiatry and Behavioral Sciences
Associate Director, University of Washington Alzheimer’s Disease Research Center
University of Washington School of Medicine
Lon Schneider, MD, MS
Professor of Psychiatry, Neurology, and Gerontology
Della Martin Chair in Psychiatry and Neuroscience
Keck School of Medicine
Director, California Alzheimer’s Disease Center
Director, Department of Psychiatry Geriatric Studies Center
Co-director, Clinical Core of the Alzheimer’s Disease Research Center (National Institutes of Health)
University of Southern California
Los Angeles, CA
Pierre N. Tariot, MD
Banner Alzheimer’s Institute
Research Professor of Psychiatry
University of Arizona College of Medicine
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Disclosures of Conflicts of Interest
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Gary Small, MD
- Consultant: AARP, Acadia, Allergan, Avanir, Biogen, Gerontological Society of America, Handok, Herbalife, Lilly, Lundbeck, McCormick Science Institute, Otsuka Pharmaceutical Development & Commercialization, Reckitt, Roche, Theravalues
- Shareholder: CereMark Pharma
- Elaine Peskind, MD
- Consultant: Genentech
- Lon Schneider, MD, MS
- Grant/Research Support: Alzheimer’s Association, Biogen, Biohaven, Lilly, National Institute on Aging, NIH, Novartis, Part the Cloud, Roche/Genentech, Washington University DIAN-TU
- Consultant: AC Immune, Alpha Cognition, Athira, BioVie, Lilly/Avid, Cognition Inc, Cortexyme, Eisai, GW Research, ImmunoBrain Checkpoint, Merck, Neurim, Otsuka/Lundbeck, Pharmatrophix, Roche/Genentech
- Other: The Lancet Commission on Dementia Prevention and Care, Della Martin Foundation. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
- Pierre N. Tariot, MD
- Consultant: AbbVie, Biogen, Cortexyme, Genentech, Lilly, Merck, National Institute on Aging, Novartis, Roche, AC Immune, Acadia, Athira Pharma, Corium, Eisai, Lundbeck, Novo Nordisk, Otsuka & Astex Pharmaceuticals, T3D Therapeutics
- Other: Academy for Continued Healthcare Learning, Miller Medical Communications.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Complete the activity (including pre- and post-activity assessments)
- Request credit using the drop-down menu
You may immediately download your certificate.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.